Healthcare Startup Laboratoy work visual


A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

ABBA Therapeutics AG
ABBA Therapeutics develops therapeutic antibodies against novel targets for cancer immunotherapy.

Alentis Therapeutics AG
Alentis Therapeutics is a biotech based in Basel, Switzerland. It discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC).

Anaveon is a late pre-clinical phase biotech based in Basel, Switzerland.  It focuses on the development of next generation IL-2 based therapeutic antibodies for tumor immunotherapy in melanoma, kidney carcinoma and lung cancer.

Avicenna Oncology
Avicenna Oncology GmbH is a biotechnology start-up, created in 2014 in Basel, Switzerland. Our lead program consists of ImmunoPayloads (ImPs), First In Class immuno-oncology therapeutics with a unique and innovating mode of action.

β-catenin project
The beta catenin project aims to develop novel therapeutics for the treatment of colorectal, lung, liver, breast, brain and ovarian cancers by removing pathological proteins from the human body.

Biotech in stealth mode
Developing novel cell engineering-based treatments.

Biotech in stealth mode
Discovery and development of new eye therapeutics for diseases with unmet medical need.

Biotech in stealth mode
Developing a novel digital therapeutic for the treatment of migraine

CellSpring analyzes human cells grown in special 3-Dimensional environments to develop new tools for diagnosing early-stage cancer.

CMET Pharmaceuticals
CMET Pharmaceuticals aims to develop novel therapies for the treatment of metastatic cancers, tailored to target circulating tumour cell clusters.

Cureab develops antibodies for cancer therapy focussing on lung, liver and colorectal cancer.

Epibloc applies a proprietary immunoprofiling platform to identify peptides that bind to specific autoantibodies involved in autoimmune diseases. The peptides are then used to develop companion diagnostics and precision drugs to eliminate only the disease causing autoantibodies.

logo Pattern BiosciencesPattern Biosciences
Next generation programmable therapies powered by Synthetic Biology.

Polyneuron Pharmaceuticals AG
Polyneuron is committed to the development of a promising new drug class to treat autoimmune disorders.

SiBreaX develops stimulus responsive silicate-based nano-/microparticles for targeted drug/compound delivery and degradable, injectable nanocomposite hydrogels for biomedical and topical applications. Leveraging its platform technology of nano-/microparticles and hydrogels, SiBreaX partners in development as well as develops own drugs and medical hydrogels.

SunRegen Healthcare AG
SunRegen develops novel drugs for neurodegenerative diseases.

Synendos-TherapeuticsSynendos Therapeutics
We develop new drugs to treat anxiety and stress disorders by modulating the activity of cannabinoid molecules already present in the brain.

T3 Pharmaceuticals AG
T3 Pharma develops the next generation bacterial cancer therapy.

The mission of TEPTHERA is to offer individualized therapeutic cancer vaccines.

VERSAMEB is a regenerative medicine research and development company.

Biotech Office Buildings